Effective
,B-galactosidase DNA revealed that alveolar epithelial cells were the primary locus of expression and that up to 1% of all alveoli contained epithelial cells expressing the transgene.
The lung is an established site for pharmaceutical intervention (1) . Compared with systemic administration, direct intrapulmonary administration is a relatively noninvasive procedure and provides high local concentrations of therapeutic agents. In addition, since the airway penetrates deeply into all areas of the lung, and since the cells lining the airway are relatively accessible, the lung has become an attractive target for gene-based therapies, and in particular for those pulmonary ailments that may be refractory to traditional small molecule intervention.
Cystic fibrosis (CF) is the most widely studied pulmonary disease where gene therapy approaches are being investigated. CF is an inherited genetic disease caused by any of over 400 separate mutations in the gene for the CF transmembrane conductance regulator (CFTR) (2) . CFTR is essential for efficient transport of chloride ions and fluid across epithelial cell membranes (3) . One therapeutic strategy is based on the introduction of cDNA for normal CFTR into pulmonary epithelia to replace the functionally defective protein. A gene therapy that leads to intracellular expression of the transgene product should ensure accurate processing, protein folding, intracellular transport, and membrane insertion.
Two approaches for introducing transgenes into cells are viral vector-based and plasmid DNA-based systems (4) . The adenoviral viral vector strategy typically results in high levels of expression (5) . However, when used for in vivo applications, the adenoviral vector approach can lead to the generation of host immune responses to viral structural components (6, 7) . In some cases, a cellular immune response is generated against adenoviral vectortransfected cells that express heterologous viral proteins (8) (9) (10) . Such immune responses render the lung refractory to subsequent administrations of adenoviral vector gene therapy.
Cationic lipids (frequently referred to as cytofectins) can be used to enhance the delivery and expression of plasmid DNA in vitro and in vivo (11, 12) , and a considerable amount of work has been reported using both viral and cationic liposome technologies to transfect lung with a principle application being CF therapy (13) (14) (15) (16) . Unlike viral vector systems, plasmid based gene therapies using cytofectins appear not to give rise to a specific immune response directed at the delivery system (17) (18) (19) . In addition, studies of the metabolic fate and toxicity of plasmid DNA have given no indication of untoward systemic effects resulting from either the plasmid DNA or the cytofectin formulation (20, 21) . The practical aspects of pharmaceutical drug production also favor plasmid based technologies (4, 11, 12) . However, the relatively low levels of in vivo plasmid DNA expression obtained with previously described cytofectin reagents somewhat offset the advantages. In this report we confirm previously published results showing that plasmid DNA, without cationic lipids, is expressed at measurable levels in mouse lung (22, 23) . Furthermore, we describe a novel cationic lipid, (± +)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide (GAP-DLRIE), which greatly enhances the expression of plasmid DNA delivered to mouse lung.
MATERIALS AND METHODS
Hexane, chloroform, and ethyl ether were from EM Science, and anhydrous ethanol was from Quantum Chemicals (Durham, NC). ( + )-3-Dimethylamino-1,2-propanediol was from Janssen Chimica. Dodecyl methane sulfonate was from Nu Check Prep (Elysian, MN). All other synthetic reagents were from Aldrich. Bulk silica G, as well as silica G and GF TLC plates, were from Analtech (nos. 14100, 01521, and 02521, respectively). Amine coated silica TLC plates were from EM Separations (Merck; no. 15647). TLC plates were visualized by spraying with 10% H2SO4 in methanol, then charring at elevated temperature (500°C for G and GF plates, 120°C for amine coated plates). Infrared spectra were obtained using a Perkin-Elmer 1310 spectrophotometer. IH-NMR spectra were from a Bruker (Billerica, MA) AC 300. High resolution mass spectroscopy was performed by the Department of Chemistry at the University of Minnesota using a VC 7070E-HF instrument in FAB mode with PEG as intemal standard. For histology, 5-bromo-4-chloro-3-indolyl f3-D-galactoside (X-Gal) substrate solution (no. 5520UC) was from GIBCO/BRL; glutaraldehyde (no. G-5882), MgCl2 (no. M-8266), potassium ferrocyanide (no. P-3289), potassium ferricyanide (no. P-3667), and N,N-dimethylformamide (no. D-8654) were from Sigma. PCDNA3CAT was purchased from Invitrogen. Dioleoylphos- tTo whom reprint requests should be addressed at: Vical Incorporated, Suite 100, 9373 Towne Centre Drive, San Diego, CA 92121.
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. To a solution of this phthalate (1.99 g, 2.75 mmol) in absolute ethanol (35 ml) anhydrous hydrazine (2.5 ml, 94 mmol) was added. The flask was flushed with argon, tightly stoppered, and stirred at ambient temperature. After 18 hr the thick slurry was diluted with chloroform (70 ml) and then vacuum filtered through a medium glass frit using an additional 70 ml of chloroform as rinse. The combined filtrates were evaporated, and the residue partitioned between chloroform (400 ml) and 0.1 M sodium hydroxide (200 ml). The aqueous phase was washed with chloroform (200, 100, then 50 ml), and the combined organic extracts dried over anhydrous sodium sulfate. Filtration and evaporation afforded a residue which was treated with high vacuum overnight then redissolved in chloroform (10 ml) (24) . VR1332 was derived by cloning the CAT gene into SalI/BamHI-digested VR1012 (25) . Vector VR1012 is a modified version of VIJ-neo provided by J. Shiver (Merck Sharp & Dohme), which is identical to VIJ (24) except that the ampicillin resistance gene was replaced with the neomycin/kanamycin resistance gene from plasmid puc4K (Pharmacia). Two LacZ constructs used in the histochemical studies were derived by cloning a nuclear or a cytoplasmic ,B-galactosidase (13-gal) gene into VR1012 giving rise to plasmids VR1411 (13-gal-nucl) and VR1412 (13-gal-cyt), respectively. The nuclear 13-gal gene was constructed by fusing at the 5' end ofLacZ coding region with an oligonucleotide encoding peptide MVKKKRK that resembles the nuclear localization signal in the simian virus 40 large T antigen.
Preparation of Liposomes and DNA Complexes. The cytofectin colipid mixtures were prepared as described (26) (43) and DC-cholesterol (37) were synthesized according to published procedures. DOPE, diphytanoyl-phosphatidylethanolamine, or cholesterol in sterile 2 ml glass vials. The dried lipid films were produced by evaporating the chloroform under a stream of nitrogen, and the vials were placed under vacuum overnight to remove solvent traces. The lipid films, consisting of 1.5 ,umol cationic lipid each, were reconstituted with 0.5-1.5 ml sterile pyrogen-free distilled water (GIBCO/BRL) and the vial was vortex mixed for 1 min at room temperature. The cationic lipid/plasmid DNA complexes were prepared by mixing equal volumes of the cationic liposomes (1-3 mM cationic lipid) with the DNA (8-16 mM in water; based on 330 molecular weight per nucleotide monomer).
Transfection of CFT1 Cells in Vitro. CFT1 is an immortalized airway epithelial cell line obtained from a CF patient (27) . Cells were seeded in 96-well tissue culture plates at 7.5 x 103 cells per well and allowed to grow for 5-7 days until confluent. Transfection of CFT1 was performed as described (26) (26) .
Detection of CAT Expression in Vivo Following Intranasal
Delivery into BALB/c Mice. Female BALB/c mice (4-6 weeks old) were anesthetized with metaphane and 100 ,ul of GAP-DLRIE/DOPE/VR1332 was administered. The complexes were delivered by either intratracheal or intranasal catheter. For intratracheal administration, a 22G steel olive tipped catheter containing cationic lipid-plasmid DNA complexes (100 ,ul) was passed down the upper palate into the trachea. For intranasal administration, a 1-cc syringe with an attached angiocath catheter filled with cationic lipid-DNA complexes (100 ,ul) was used to administer droplets of the complexes into the nasal passage. The mice were euthanized 2-35 day postinstillation, and the lungs were harvested, frozen, pulverized, and extracted as described (25) The number of X-Gal positive and negative alveoli in randomly selected sections was counted by using light microscopy and a calibrated ocular grid. In cross section, each alveolus was bordered by 2-5 alveolar epithelial cells. An alveolus was scored as (+) if it contained 1 or more X-Gal (+) alveolar epithelial cells. RESULTS GAP-DLRIE Chemistry. The structure of GAP-DLRIE is shown in Fig. 1 . The basic skeleton of GAP-DLRIE is typical of the 2,3-dioxy-propaniminium class of cationic lipids which also includes (+)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (DMRIE), DOTAP, DOTMA, and DOSPA. This class of cationic lipids has two hydrophobic chains appended to a quatemary ammonium moiety via a polar dioxy-propyl group in a manner affording a central glycerol-like structure. GAP-DLRIE is readily prepared from commercial reagents in about 30% overall yield (see Materials and Methods).
Enhanced Transgene Expression in Mouse Lung. The amount of CAT expressed was determined after intralung administration ofplasmid either alone or as plasmid/cytofectin complexes. A total of 130 ,ug plasmid either alone or complexed with a cytofectin was administered intranasally in 100 Al water to anesthetized BALB/c mice. After 2 days, the lungs were harvested and assayed for CAT. A comparison of two CAT plasmids (Fig. 2) showed that naked VR1332 was 18-fold more active than a commercial pCDNA3CAT construct, and 9 of the 12 cytofectin formulations tested enhanced the level of expression obtained with VR1332 alone. An optimized GAP-DLRIE/DOPE formulation yielded nearly 13 ng CAT per 100 mg lung tissue, representing a 140-fold increase in expression over plasmid DNA alone. It is noteworthy that an optimized formulation of DOSPA/DOPE (1.5:1, cytofectin/plasmid) gave about 11 times the naked DNA signal, while a DOSPA formulation stoichiometrically equivalent to that illustrated for GAP-DLRIE (1:4, cytofectinfplasmid) substantially decreased the expression from the naked plasmid. All other formulations yielded activity less than 4 times that of naked DNA.
Colipid Optimization. Cationic lipids generally produce better transgene expression when mixed with a colipid prior to complexing with plasmid DNA (11) . DOPE is an effective colipid for facilitating Rosenthal-type cationic lipid transfection of cells in vitro, and the molar ratio of DOPE to cytofectin has been an important variable (26) . Here, the transfection efficiency of GAP-DLRIE, formulated alone or at three different molar ratios of DOPE, was examined in a standard in vitro 13-gal microassay with the CFT1 cell line, and in the in vivo murine lung assay using both intranasal and cannula intubation. The results of these assays are shown in Fig. 3 . Fig.  3A indicates that a 1:3 molar ratio of GAP-DLRIE/DOPE was the most effective in CFT1 cells in vitro, while Fig. 3B shows that a 1:1 molar ratio was the most effective in vivo. The in vivo DOPE optimization was the same whether the formulation was administered intranasally or by intratracheal instillation. However, intranasal administration resulted in a higher level of expression than intratracheal instillation. Further in vivo studies using intranasal instillation were conducted to determine whether other neutral colipids would substitute for DOPE. Diphytanoyl-phosphatidylethanolamine substituted for DOPE at a similar optimal content of 1:1 molar ratio, however its potency was about 3-fold less than DOPE, and DOPC and cholesterol also produced a very slight enhancement in transgene expression, but their potencies were about 15-fold less than DOPE (data not shown). DNA (Fig. 4) . Abundant CAT expression could be seen by day 1, and this level was maintained for at least 3 additional days. By day 7, expression had declined to about 30% of day 1 levels, and a further gradual decline was seen until day 23, when most of the remaining CAT had disappeared. Groups of animals that received a single dose on day 0 were given a second dose on day 21, and CAT was measured at days 22, 23, 24, 25, 28, and 35 (corresponding to the first six time points examined after the first administration). There was a statistically significant increase in expression on days 1, 2, and 3 after the second dose, compared with the animals receiving only a single dose. Expression levels declined to near baseline levels by 14 days after the second dose.
In Situ Localization of Reporter Gene Expression. A histological examination of X-Gal-stained cryostat sections was conducted of murine lungs transfected with two different plasmids encoding the 13-gal protein, with (,B-gal-nucl) or without (P3-gal-cyt) a nuclear localization signal. Representative photomicrographs of X-Gal stained lung sections are shown in Fig. 5 . Fig. 5 A-C are from animals that were administered the plasmid encoding cytoplasmic f-gal, and Fig. 5 D-F are from animals dosed with the plasmid encoding nuclear localized reporter gene. In many cases the cytoplasmic expression appeared to spread over an entire alveolus or several alveoli, whereas the nuclear localized ,B-gal was confined to the alveolar cell nuclei. The predominant morphology of X-Gal(+) lung cells is consistent with the morphology of perialveolar epithelial cells (29) and not with the morphology of alveolar macrophagic cells (30) . The number of alveoli containing X-Gal positive cells was determined for each section and the data are shown in Table 2 . A total of 1282 sections were analyzed from 10 mice receiving GAP-DLRIE/ DOPE liposome lacZ DNA (VR1411, VR1412) complexes. Of these, 960 sections (-75%) exhibited cellular a-gal expression. ,3-Gal expression was observed in the lungs of all of the animals receiving intranasal GAP-DLRIE/DOPE/pLacZ complexes. Within each lung (numbered 1-10), the percentage of alveoli containing at least one X-Gal(+) epithelial cell varied from 0.05% to 1.15% of the total number of alveoli per section. No X-Gal staining was evident in control lungs receiving GAP-DLRIE/DOPE liposome CAT DNA complexes (lung numbers 11, 12, and 13). No X-Gal staining was observed with naked VR1332 CAT plasmid alone (data not shown).
DISCUSSION
Reporter gene expression has been observed in vivo after naked DNA administration to lung (22, 23) , heart (31), liver (32) , skin (33) , vascular endothelium (34), tumor (35) , and numerous tissues after systemic administration (36) . Thus, to establish that a given formulation improves in vivo plasmid delivery and expression, a naked plasmid DNA control must be used. In the present work, a new cationic lipid molecule, GAP-DLRIE, is described that can enhance functional in vivo gene delivery in mouse lung by more than 2 orders of magnitude over that achieved by delivery of naked DNA. GAP-DLRIE emerged as one of the most potent of more than 100 compounds tested for their ability to enhance the expression of the CAT reporter gene in mouse lung following intranasal administration. The transfection activity in mouse lung of GAP-DLRIE was compared with two cytofectins now in clinical use (DMRIE and DC-cholesterol), and a variety of commercially available reagents (DDAB, DOSPA, EDLPC, EDMPC, DOTAP, DOTMA), and with DLRIE another compound from our laboratory that was previously described (12) . All of the compounds examined exhibited substantial in vitro activity but only one of these (DOSPA) showed activity in lung that approached even 10% of that achieved with GAP-DLRIE. GAP-DLRIE was at least 50 times more active than the other commercially available cationic lipids tested. Thus, GAP-DLRIE provided 140-fold more activity than plasmid alone and was clearly superior to all other cationic lipids tested. There was no obvious correlation between the in vitro activity of the compounds and their in vivo activity in mouse lung.
The persistence of CAT expression following transfection with GAP-DLRIE/DOPE/pDNA formulations in vivo was also assessed. High levels of expression were observed at days 1-3, which declined rapidly to about 30% of the maximum level by day 14 (6, 7, 8, 39) . This has been attributed to a host immune response against adenoviral antigens. In contrast, repeat transfection was obtained using GAP-DLRIE/DOPE/CAT complexes, suggesting that an immunological response may not limit the repetitive utilization of this type of synthetic vector. Several studies have been conducted with cationic lipid-plasmid DNA formulations to look for immune responses against cationic lipid or plasmid DNA, and none have been found (18, 20 Two days after intranasal administration of GAP-DLRIE complexed with LacZ DNA encoding cytoplasmically or nuclear targeted ,3-gal or CAT, mouse lungs were cut into quarters and the quarters separately embedded for cryostat sectioning. Random sections from each quadrant of all 13 mice were processed for X-Gal staining. Data are expressed as the total number of random sections examined per lung, number of sections that contained any X-Gal(+) cells, the number of alveoli containing at least 1 X-Gal(+) cell, the average total number of alveoli present per section, and the average percent of X-Gal(+) alveoli per section. jority of staining appeared to be localized in the alveolar epithelial cells, and few X-Gal-positive regions were observed in the larger bronchiolar airway cells. It is unclear whether the degree of specificity in transfection of alveolar cells in the present experiments reflects delivery aspects, or whether it represents preferential cellular transfection. It is also unclear just how much and how widely a therapeutic transgene such as the CFIR gene needs to be introduced to offer a therapeutic benefit, although some estimates have been made based on conductance data from in vitro systems (39) . In addition, the target cells for a CF therapy have yet to be defined, although epithelial cells lining the lower airways and in submucosal glands have been suggested as regions where correction of the chloride imbalance will lead to a CF treatment (40) .
GAP-DLRIE is a member of the 2,3-dioxy-propaniminium cytofectin class which also includes DMRIE, DOTAP, DOTMA and DOSPA, and it is, therefore, a member of the most widely used skeletal type of cytofectins. GAP-DLRIE possesses fully saturated and substantially shorter alkyl chains than DOTAP, DOTMA or DOSPA, which should result in a more water-soluble, less hydrophobic molecule, with a higher critical micelle concentration and a higher spontaneous rate of monomer lipid transfer through the aqueous phase. These physical properties will also be influenced by the presence of a primary amine appended to the quaternary ammonium group in the polar head region of GAP-DLRIE. Protonating the primary amine would provide a formal charge of +2 to GAP-DLRIE and increase the hydrophilic character of the compound relative to singly charged cytofectin analogs. Using the second pKa of propylene diamine (9.3) as a model, an equilibrium between the protonated and deprotonated forms of GAP-DLRIE in liposomes might be anticipated at the physiological pH of 7.4. The degree of protonation of GAP-DLRIE liposomes will be affected by surface pH which is expected to be 3-4 pH units higher than the bulk pH (41) . Thus, when cytofectin-DNA complexes comprising GAP-DLRIE enter into the low pH endosomal compartment, their protonation state and physical organization may change leading to release of DNA from the endosome. Similarly, the amine may act as a base at an endosomal pH of 5, thereby augmenting plasmid delivery to the cytoplasm in a manner postulated for lysosomotropic agents (26) . Certain consequences of introducing a single primary amine into a cytofectin have recently been revealed (42) . Thus, the shorter alkyl chains of GAP-DLRIE, and its complex polar headgroup consisting of quaternary and primary amino groups, may together impart physical properties to the cationic lipid-DNA complexes which result in optimal, (i) DNA-cationic lipid interaction and lipid-DNA packing, (ii) cell surface interaction, (iii) endosomal escape (or endosomal avoidance), and (iv) intracellular dissociation of the cationic lipid-DNA complexes.
Numerous cationic lipids that have been shown to be highly effective for in vitro (26, (43) (44) (45) transfection are poorly active in vivo. In contrast, the level of expression obtainable with the newly designed cationic lipid molecule, GAP-DLRIE, can reach 450 times the level obtainable with naked plasmid DNA in some animals. The results reported here also indicate that the ability of specific cationic lipids to enhance in vivo expression of plasmid DNA must be determined with reference to the target cell in the particular tissue to which the DNA is being administered. Similarly, the amount of DOPE required for optimal in vitro and in vivo activity differ and, therefore, the efficacy of cationic lipid formulations for in vivo gene delivery to lung cannot be straightforwardly predicted from in vitro transfection assays, and must also be determined by direct in vivo assay.
Several clinical studies using plasmid DNA based vectors for the treatment of CF patients are underway or completed (10, 18, 37) . The results reported here suggest that an optimal cationic delivery vehicle will elicit a dramatic enhancement in DNA delivery and expression. Future plans include testing lipids of this type in a clinical setting to ascertain whether the improved characteristics of such new formulations developed using a murine model will also improve efficacy in human CF patients.
